2.4.1. Alice Chung, Doug Liou, Scott Karlan, Alan Waxman, Kayo Fujimoto, Masanobu Hagiike, and Edward H. Phillips Preoperative FDG-PET for Axillary Metastases in Patients With Breast Cancer Arch Surg, Aug 2006; 141: 783 – 789.
2.4.2. S.-J. Kim, S.-k. Kim, E. S. Lee, J. Ro, and S. h. Kang Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy Ann. Onc., Sep 2004; 15: 1352 – 1357.
2.4.3. Amy Tran, Betty S. Pio, Bahareh Khatibi, Johannes Czernin, Michael E. Phelps, and Daniel H.S. Silverman 18F-FDG PET for Staging Breast Cancer in Patients with Inner-Quadrant Versus Outer-Quadrant Tumors: Comparison with Long-Term Clinical Outcome J. Nucl. Med., Sep 2005; 46: 1455 – 1459.
2.4.4. Joerg Dose Schwarz, Michael Bader, Lars Jenicke, Gabriele Hemminger, Fritz Jänicke, and Norbert Avril Early Prediction of Response to Chemotherapy in Metastatic Breast Cancer Using Sequential 18F-FDG PET J. Nucl. Med., Jul 2005; 46: 1144 – 1150.
2.4.5. Cecelia S. Yap, Marc A. Seltzer, Christiaan Schiepers, Sanjiv S. Gambhir, Jyotsna Rao, Michael E. Phelps, Peter E. Valk, and Johannes Czernin Impact of Whole-Body 18F-FDG PET on Staging and Managing Patients with Breast Cancer: The Referring Physician’s Perspective J. Nucl. Med., Sep 2001; 42: 1334 – 1337.
2.4.6. Flavio Crippa, Roberto Agresti, Ettore Seregni, Marco Greco, Claudio Pascali, Anna Bogni, Carlo Chiesa, Vinicio De Sanctis, Vincenzo Delledonne, Bruno Salvadori, Monica Leutner, and Emilio Bombardieri Prospective Evaluation of Fluorine-18-FDG PET in Presurgical Staging of the Axilla in Breast Cancer J. Nucl. Med., Jan 1998; 39: 4 – 8.
2.4.7. Eric L. Rosen, William B. Eubank, and David A. Mankoff FDG PET, PET/CT, and Breast Cancer Imaging RadioGraphics, Oct 2007; 27: S215 – S229.
2.4.8. Hyo Soon Lim, Woong Yoon, Tae Woong Chung, Jae Kyu Kim, Jin Gyoon Park, Heoung Keun Kang, Hee Seung Bom, and Jung Han Yoon FDG PET/CT for the Detection and Evaluation of Breast Diseases: Usefulness and Limitations RadioGraphics, Oct 2007; 27: S197 – S213. “Although FDG PET/CT may have limited diagnostic value for detecting small primary breast tumors, well-differentiated breast cancer, or regional lymph node involvement, it is superior to conventional imaging modalities for detecting distant metastases and recurrences and for monitoring the response to therapy.”